Context Therapeutics to Showcase Innovative T Cell Therapy at SITC
Context Therapeutics Inc. (NASDAQ: CNTX), a company dedicated to developing T cell engagers for solid tumors, is excited to announce its participation in a significant event in the oncology community. They will present their encouraging findings on CTIM-76, a groundbreaking Claudin 6 x CD3 bispecific antibody, at the Society for Immunotherapy of Cancer's (SITC) annual meeting.
Details of the Presentation
The poster presentation is set to take place during the SITC's 39th Annual Meeting. This annual gathering is a hub for the latest advancements in cancer treatment and research. Context would like to invite attendees to engage with the innovative research surrounding CTIM-76, which aims to revolutionize treatment for solid tumors.
Presentation Overview
The presentation will detail the determination of the first-in-human dose of the promising T cell-redirecting bispecific antibody designed to target Claudin 6. This research is particularly vital as Claudin 6 is known to be enriched in various solid tumors such as ovarian and lung cancers.
Key Authors
The study will be presented by a team of distinguished authors including Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz, who have all played crucial roles in the development of this innovative therapeutic approach.
Understanding CTIM-76: A Glance into Innovative Therapy
CTIM-76 is a leading-edge bispecific antibody that engages T cells to target Claudin 6. Its potential has been highlighted through robust preclinical research. This research indicates promising aspects regarding its safety profile and efficacy, making it a noteworthy candidate for treating patients suffering from various solid tumors.
Context Therapeutics: A Leader in Innovative Medical Solutions
Context Therapeutics Inc. (NASDAQ: CNTX) is at the forefront of biopharmaceuticals focusing on T cell engaging bispecific antibodies for solid tumors. Their product pipeline illustrates a commitment to addressing unmet medical needs. Alongside CTIM-76, they are advancing other therapeutics such as CT-95 and CT-202, showcasing their dedication to innovative cancer treatments.
Join the Conversation
For more insights and detailed information about Context Therapeutics, interested individuals are encouraged to visit their official website. The company maintains an active presence on platforms like X and LinkedIn, where they share updates on their groundbreaking research and engagement within the medical community.
Frequently Asked Questions
What is CTIM-76?
CTIM-76 is a bispecific antibody targeting Claudin 6, designed to engage T cells and provide innovative treatment options for solid tumors.
When and where is the SITC presentation?
The presentation is on November 9, 2024, at the SITC 39th Annual Meeting. It will occur at the Exhibit Halls AB.
Who are the main contributors to the research?
The research team includes Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
What can attendees expect from the presentation?
Attendees can look forward to insights regarding the first-in-human dose determination for CTIM-76 and its implications in cancer therapy.
How is Context Therapeutics positioned in the industry?
Context Therapeutics Inc. is recognized for its innovative approach in developing T cell engaging bispecific antibodies, with a strong commitment to advancing cancer treatments.
